Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Nontuberculous Mycobacterial Lung Disease

Pulmonary & Respiratory

Nontuberculous Mycobacterial Lung Disease (NTM) Clinical Trials

Also called NTM Lung Disease, NTM, NTM-PD, Nontuberculous Mycobacterial Pulmonary Disease, Non-Tuberculous Mycobacterial Lung Disease, Non-Tuberculous Mycobacteria Pulmonary Disease, Nontuberculous Mycobacterial Pulmonary Infection, Nontuberculous Mycobacterium Infection, Non-Tuberculous Mycobacterial Pneumonia, Pulmonary Non-Tuberculous Mycobacterial Infection, MAC Lung Disease, Mycobacterium Avium Complex Lung Disease, Mycobacterium Avium Complex Pulmonary Disease, MAC-PD, Mycobacterium Avium-Intracellulare Infection, Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Lung Disease, Mycobacterium Abscessus Infection, Pulmonary Disease Due to Mycobacteria, Mycobacteria Other Than Tuberculosis, MOTT

Mycobacteria are a family of bacteria. Mycobacterium tuberculosis causes tuberculosis and Mycobacterium leprae causes leprosy, and the rest of the family are called nontuberculous mycobacteria.

In plain words, NTM lung disease is a slow lung infection caused by germs from soil and water that are related to tuberculosis but usually do not spread between people. It causes a cough and tiredness that last for months, and treatment, when it is needed, means a long course of antibiotics.

Get an email when new Nontuberculous Mycobacterial Lung Disease trials open or the FDA decides. Get alerts

Nontuberculous Mycobacterial Lung Disease

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review1

Arikayce, Jan 28, 2027

FDA-approved medicines1

Arikayce

Nontuberculous Mycobacterial Lung Disease has 1 FDA-approved medicine, 30 open or active clinical trials, and a pending FDA decision on Arikayce, due Jan 28, 2027.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

More about Nontuberculous Mycobacterial Lung Disease

The 2020 ATS/ERS/ESCMID/IDSA guideline counts more than 190 species and subspecies. They live in soil and water, and most people who breathe them in never get sick. NORD says most evidence shows the infection is picked up from the environment rather than passed between people.

Keep reading about Nontuberculous Mycobacterial Lung Disease

Mycobacterium avium complex, the group that includes M. avium, M. intracellulare and M. chimaera, accounts for about half of all NTM infections, according to NORD. Other species include M. kansasii and M. abscessus, which grows fast and is harder to treat; NORD gives treatment success rates of 41-46% for M. abscessus.

The germs take hold most easily in airways that cannot clear mucus well. NORD describes mucus in damaged airways as a home where NTM can hide from the immune system. Over years, repeated infection can widen and scar the airways (bronchiectasis) or hollow out cavities in the upper lungs, and untreated cavitary disease can lead to scarring and breathing failure.

The 2020 guideline sets 3 requirements before NTM lung disease is diagnosed. The first is lung or body-wide symptoms. The second is a chest X-ray or CT scan showing nodules, cavities or bronchiectasis with small nodules, after other diagnoses have been ruled out. The third is the same NTM species grown from at least 2 separate sputum samples or from 1 bronchoscopy wash. A lung biopsy showing mycobacterial changes, plus a positive NTM culture, also counts. A single positive sputum culture is not enough, because NTM from the environment can end up in a sample. MAC grows slowly, taking 2 to 4 weeks on solid culture media, so results take time (NORD).

Not everyone needs antibiotics right away, and NORD notes that some slow infections are watched with regular check-ups. For people who meet the criteria, the guideline suggests starting treatment rather than waiting, especially when a sputum smear is positive or the lungs have cavities. The guideline says that choice should weigh the infecting species and the person's own priorities.

For MAC that is still sensitive to macrolide antibiotics, the guideline recommends a regimen of at least 3 drugs that includes a macrolide. Its preferred regimen is azithromycin (or clarithromycin), a rifamycin such as rifampin (or rifabutin) and ethambutol. The guideline prefers azithromycin because it is better tolerated, has fewer drug interactions and is taken once a day.

For the milder nodular bronchiectatic form, the guideline suggests taking the 3 drugs 3 times a week. For cavitary or advanced disease it suggests daily doses, with intravenous amikacin or streptomycin added at the start. Treatment continues for at least 12 months after sputum cultures turn negative.

When cultures are still positive after 6 months, the guideline recommends adding amikacin liposome inhalation suspension, sold as Arikayce. For newly diagnosed MAC, the 2020 guideline suggested not using inhaled amikacin at the start, a recommendation written before Insmed's ENCORE trial reported results in 2026.

These long courses are hard to stay on, and NORD lists stomach upset, hearing loss and liver problems among the side effects. NORD also describes airway clearance (chest physical therapy, nebulized salt water, postural drainage and oscillation vests), surgery for some localized disease, and steps against reinfection. Those steps include setting water heaters to at least 130°F, using bathroom and kitchen fans, avoiding hot tubs and wetting potting soil before handling it.

What are the symptoms of Nontuberculous Mycobacterial Lung Disease?

These are common symptoms of Nontuberculous Mycobacterial Lung Disease, and how strong they are varies from person to person.

  • A cough that lasts for weeks or months, often bringing up mucus (sputum)
  • Tiredness (fatigue)
  • Shortness of breath (dyspnea)
  • Fever, night sweats and loss of appetite
  • Weight loss without trying
  • Coughing up blood (hemoptysis) or chest pain in some people
  • Chest infections that keep coming back and slowly damage the airways

Who gets Nontuberculous Mycobacterial Lung Disease?

NTM lung disease is much more common in older adults and somewhat more common in women. In the 2020 claims study, the rate at 65 or older was about 4 times the overall rate. Women also had a higher rate than the population as a whole, 16.78 against 11.70 per 100,000 in 2015.

NORD describes 2 common patterns. The nodular bronchiectatic form mostly affects thin, middle-aged or older women of white or Asian descent, often with no history of smoking or lung disease. Some of them have a sunken chest (pectus excavatum), a curved spine (scoliosis), mitral valve prolapse or a single change in the cystic fibrosis gene. The cavitary form, which leaves holes in the upper lungs, is more common in people who smoke or have COPD.

Other lung conditions raise the risk, including bronchiectasis, COPD, cystic fibrosis, primary ciliary dyskinesia and alpha-1 antitrypsin deficiency, according to NORD. Rare immune defects and medicines that weaken the immune system, such as TNF blockers, also raise it. People with no earlier lung disease can be affected too.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Nontuberculous Mycobacterial Lung Disease?

There is currently 1 FDA-approved medication for Nontuberculous Mycobacterial Lung Disease.

amikacin
Insmed Incorporated
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Nontuberculous Mycobacterial Lung Disease treatment

Charity funds and drugmaker programs for Nontuberculous Mycobacterial Lung Disease, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Nontuberculous Mycobacterial Lung Disease, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

How Nontuberculous Mycobacterial Lung Disease is diagnosed

NTM lung disease is an infection picked up from the environment, not an inherited condition. NORD notes that rare inherited immune defects, such as interferon gamma receptor, STAT1 or GATA2 deficiency, raise the risk. Some people with the nodular form also carry a single change in the cystic fibrosis gene.

Trusted Nontuberculous Mycobacterial Lung Disease resources

Reputable organizations and medical references for learning more about Nontuberculous Mycobacterial Lung Disease, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Nontuberculous Mycobacterial Lung Disease

Use this Nontuberculous Mycobacterial Lung Disease clinical trial finder to see the 20 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. Of these, 12 test a treatment and 8 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Arikayce (amikacin liposome inhalation suspension), due January 28, 2027. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

30 active trials worldwide
Filter:
Sort:
RecruitingObservational study, no treatment givenRecently updatedNCT00018044

Study of Mycobacterial Infections

Intervention: Clofazimine

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

This study will examine the symptoms, course of disease and treatment of non-tuberculous mycobacterial (NTM) infections, as well as the genetics involved in these infections. Patients with NTM have recurrent lung infections and sometimes infections of the skin and other organs as...

Ages up to 100 Years1 location
Started Jan 2001Updated yesterdayCompletion date not listed
RecruitingTreatment trialPhase 4Recently updatedNCT07084402

Short-term Bactericidal Effect of Contezolid in MAC-PD

Intervention: Contezolid, Azithromcyin, Rifampicin (RIF), Ethambutol

Sponsor: Bin Cao · MicuRx

The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are:

Ages 18 Years to 75 Years3 locations
Started Jul 2025Updated 2 weeks agoEst. Jul 2027 (~8 months)
RecruitingTreatment trialPhase 4Recently updatedNCT07213765

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

Intervention: Contezolid, Azithromycin, Azithromycin, Ethambutol (E), Ethambutol (E), Rifampicin (R), Rifampicin (R)

Sponsor: Bin Cao · MicuRx

The goal of this clinical trial is to learn if adding contezolid works to shorten the length of treatment in mycobacterium avium pulmonary disease in adults. It will also learn about the safety of extended usage of contezolid. The main questions it aims to answer are:

Ages 18 Years to 75 Years
Started Jul 2025Updated 2 weeks agoEst. Sep 2028 (~1y 10m)
RecruitingTreatment trialPhase 4Recently updatedNCT07174076

Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease

Intervention: cordyceps sinesis capsule, cordyceps sinesis capsule placebo

Sponsor: Bin Cao · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

The goal of this clinical trial is to learn if cordyceps sinesis capsule (Bailiing Capsule) works to prevent the recurrence of microbiologically cured mycobacterium avium complex pulmonary disease in adults. The main questions it aims to answer are:

Ages 18 Years to 75 Years
Started Jul 2025Updated 2 weeks agoEst. Jul 2028 (~1y 8m)
RecruitingTreatment trialPhase 4Recently updatedNCT04921943

Hypertonic Saline for MAC

Intervention: Hypertonic saline, Azithromycin, Ethambutol, Rifampin

Sponsor: Oregon Health and Science University

The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.

Ages 18 Years+1 location
Started May 2021Updated 1 month agoEst. Jan 2027 (~1 month)
Find Nontuberculous Mycobacterial Lung Disease trials near you, ranked by distance →
Active trial locations15 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+7 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 4
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Nontuberculous Mycobacterial Lung Disease trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Nontuberculous Mycobacterial Lung Disease foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Nontuberculous Mycobacterial Lung Disease patient communities

Facebook groups, Reddit communities and YouTube channels where Nontuberculous Mycobacterial Lung Disease patients, caregivers and advocacy groups talk.

Questions people ask about Nontuberculous Mycobacterial Lung Disease